Medicinova (MNOV) vs Nutriband (NTRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed Nutriband (NTRB) over the past year, gaining 26.2% versus a loss of 28.8%. Over five years, NTRB leads with a -11.2% price change compared with -59.7% for MNOV. Medicinova is the larger company by market cap ($75.8 million vs $73.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | NTRB |
|---|---|---|
| Share price | $1.54 | $6.05 |
| Market cap | $75.80M | $73.54M |
| 1-day change | -4.35% | -10.44% |
| YTD return | +17.56% | +33.26% |
| 1-year return | +26.23% | -28.82% |
| 5-year return | -59.69% | -11.15% |
| EPS (TTM) | $-0.21 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $9.19 |
| 52-week low | $1.17 | $2.80 |
| Distance from 52-week high | -60.51% | -34.13% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +435.71% | +147.93% |
| Average volume | 322.57K | 62.42K |
| Shares outstanding | 49.22M | 12.16M |
| Employees | 6 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed NTRB by 55.1 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Healthcare · Biotechnology · 6 employees
About Nutriband
NTRB stock →Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.
Healthcare · Biotechnology
MNOV vs NTRB FAQ
Which is bigger, Medicinova or Nutriband?
Medicinova (MNOV) is larger, with a market capitalization of $75.80M compared with $73.54M for Nutriband (NTRB).
Which stock has performed better over the past year, MNOV or NTRB?
MNOV returned +26.23% over the past 12 months, compared with -28.82% for NTRB (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and Nutriband in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.